$3.72 -0.36 (-8.94%)

Molecular Partners AG American Depositary Shares (MOLN)

🚫 Molecular Partners AG American Depositary Shares does not pay dividends

Company News

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
GlobeNewswire Inc. • Molecular Partners Ag • October 30, 2025

Molecular Partners announced progress on its Radio-DARPin MP0712 targeting DLL3, filed an IND application, and expects Phase 1 trial launch in late 2025. The company also reported promising results for MP0533, a multispecific T cell engager for AML, and maintains a strong financial position with cash runway until 2028.

Wall Street Breakfast: The Week Ahead
Seeking Alpha • Wall Street Breakfast • December 10, 2023

Get the latest financial updates and insights with Wall Street Breakfast's daily podcast available on Seeking Alpha, iTunes, and Spotify.

ORCLCOSTDRICHWYINTCCASY
Benzinga's Top Ratings Upgrades, Downgrades For August 29, 2022
Benzinga • Benzinga Insights • August 29, 2022

Upgrades According to Argus Research, the prior rating for AstraZeneca PLC (NASDAQ:AZN) was changed from Hold to Buy. For the second quarter, AstraZeneca had an EPS of $0.86, compared to year-ago quarter EPS of $0.45. At the moment, the stock has a 52-week-high of $71.70 and a 52-week-low of $55.50. AstraZeneca closed at $66.32 at the end of the ...

DENNHAINXENEAZNAPLECHH
Molecular Partners AG (MOLN) Q4 2021 Earnings Call Transcript
The Motley Fool • [email protected] (Motley Fool Transcribing) • March 16, 2022

MOLN earnings call for the period ending December 31, 2021.

Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates
Zacks Investment Research • Zacks Equity Research • January 12, 2022

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.

BIIBAMGNALLOABSI